U.S. markets closed
  • S&P 500

    4,166.45
    -55.41 (-1.31%)
     
  • Dow 30

    33,290.08
    -533.37 (-1.58%)
     
  • Nasdaq

    14,030.38
    -130.97 (-0.92%)
     
  • Russell 2000

    2,237.75
    -49.71 (-2.17%)
     
  • Crude Oil

    71.50
    +0.46 (+0.65%)
     
  • Gold

    1,763.90
    -10.90 (-0.61%)
     
  • Silver

    25.84
    -0.01 (-0.04%)
     
  • EUR/USD

    1.1865
    -0.0045 (-0.38%)
     
  • 10-Yr Bond

    1.4500
    -0.0610 (-4.04%)
     
  • GBP/USD

    1.3809
    -0.0115 (-0.83%)
     
  • USD/JPY

    110.1500
    -0.0810 (-0.07%)
     
  • BTC-USD

    35,490.30
    -76.22 (-0.21%)
     
  • CMC Crypto 200

    888.52
    -51.42 (-5.47%)
     
  • FTSE 100

    7,017.47
    -135.96 (-1.90%)
     
  • Nikkei 225

    28,964.08
    -54.25 (-0.19%)
     

Oragenics' COVID-19 Related Deal Pushes The Stock Higher

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Oragenics Inc (NYSE: OGEN) stock is soaring higher after announcing a deal related to its Terra CoV-2 vaccine candidate against COVID-19.

  • Oragenics has reached an agreement with Biodextris that will allow it to use Biodextris' BDX100, BDX300, and BDX301 proteosome-based adjuvants in the Terra CoV-2 vaccine.

  • Adjuvants are added to vaccines to enhance their immunogenicity. BDX100, BDX300, and BDX301 are proteosome-based adjuvants comprised of proteins and lipopolysaccharides with the benefits of intranasal vaccine administration.

  • Oragenics plans to start with animal testing of the vaccine in combination with the adjuvants.

  • The deal between Oragenics and Biodextris also allows for a potential expansion in the future. That includes use in a commercial vaccine if Terra CoV-2 gets approval from the FDA.

  • Price Action: OGEN shares increased 38.5% at $1.17 in market trading hours on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.